Clinical Trial: Improve the Survival Rate of Chinese Children and Adolescents With Non-Hodgkin's Lymphoma
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title:
Brief Summary: Non-Hodgkin's lymphoma is an aggressive malignance disease in children and adolescents. This study was designed to evaluate the efficacy and toxicity of the modified NHL-BFM-90 protocol in Chinese children and adolescents with Non-Hodgkin's lymphoma.
Detailed Summary: Non-Hodgkin's Lymphoma (NHL) in children and adolescents include Burkitt's lymphoma (BL), diffuse large B cell lymphoma (DLBL), anaplastic large cell lymphoma (ALCL) and lymphoblastic lymphoma (LBL). These subtypes of NHL are an aggressive group of diseases. At present, in developed countries, 80 to 90% of children with NHL are cured by intensive, risk-adapted chemotherapy.The best protocols include BFM-90, LMB-89 and FAB/LMB/96. However, in developing countries, such as those with low and moderate incomes, the limited availability of resources is an obstacle for using these complicated and intensive protocols.As such, very simple protocols, such as the CHOP protocol, were often used to treat children and adolescents with NHL, thus resulting in poor survival rates. To improve the survival rate of Chinese children and adolescents with NHL, This study was designed to evaluate the efficacy and toxicity of this modified NHL-BFM -90 protocol in Chinese children and adolescents with NHL.
Sponsor: Sun Yat-sen University
Current Primary Outcome: The event free survival (EFS) [ Time Frame: Up to 5 years ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Number of Participants with Adverse Events [ Time Frame: Up to 5 years ]
Original Secondary Outcome: Same as current
Information By: Sun Yat-sen University
Dates:
Date Received: December 21, 2012
Date Started: March 1998
Date Completion:
Last Updated: January 3, 2013
Last Verified: January 2013